However, at the latest 2015 St Gallen International Breast Cancer Conference, the panel recommended Ki67-LI should be interpreted upon local laboratory values, and ER+/HER2− BCs could not be classified as two distinctive groups by IHC surrogate markers, as they belong to a spectrum of disease [9]. The gene discussed is MKI67; the disease is breast carcinoma.